GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Omnicell Inc (NAS:OMCL) » Definitions » EV-to-EBITDA

OMCL (Omnicell) EV-to-EBITDA : 13.22 (As of May. 24, 2025)


View and export this data going back to 2001. Start your Free Trial

What is Omnicell EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Omnicell's enterprise value is $1,309 Mil. Omnicell's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $99 Mil. Therefore, Omnicell's EV-to-EBITDA for today is 13.22.

The historical rank and industry rank for Omnicell's EV-to-EBITDA or its related term are showing as below:

OMCL' s EV-to-EBITDA Range Over the Past 10 Years
Min: 11.86   Med: 28.65   Max: 58.55
Current: 13.22

During the past 13 years, the highest EV-to-EBITDA of Omnicell was 58.55. The lowest was 11.86. And the median was 28.65.

OMCL's EV-to-EBITDA is ranked worse than
54.4% of 500 companies
in the Healthcare Providers & Services industry
Industry Median: 11.93 vs OMCL: 13.22

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-05-24), Omnicell's stock price is $28.23. Omnicell's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $0.460. Therefore, Omnicell's PE Ratio (TTM) for today is 61.37.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Omnicell EV-to-EBITDA Historical Data

The historical data trend for Omnicell's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omnicell EV-to-EBITDA Chart

Omnicell Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 48.23 46.74 26.13 30.45 22.93

Omnicell Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.59 23.48 36.73 22.93 16.41

Competitive Comparison of Omnicell's EV-to-EBITDA

For the Health Information Services subindustry, Omnicell's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Omnicell's EV-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Omnicell's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Omnicell's EV-to-EBITDA falls into.


;
;

Omnicell EV-to-EBITDA Calculation

Omnicell's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=1308.795/98.978
=13.22

Omnicell's current Enterprise Value is $1,309 Mil.
Omnicell's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $99 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Omnicell  (NAS:OMCL) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Omnicell's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=28.23/0.460
=61.37

Omnicell's share price for today is $28.23.
Omnicell's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.460.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Omnicell EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Omnicell's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Omnicell Business Description

Traded in Other Exchanges
N/A
Address
4220 North Freeway, Fort Worth, Santa Clara, CA, USA, 76137
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
Executives
Randall A Lipps director, officer: President and CEO 1101 EAST MEADOW DR, PALO ALTO CA 94303
Mark W Parrish director BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL
Kaushik Ghoshal director 9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
Christine Marie Mellon officer: EVP, Chief People Officer 590 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Nchacha Etta officer: EVP & CFO 4220 NORTH FREEWAY, FORT WORTH TX 76137
Joanne B Bauer director 1400 HOLCOMB BRIDGE ROAD, ROSWELL GA 30076-2199
Scott Peter Seidelmann officer: EVP, Chief Commercial Officer 590 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Peter J. Kuipers officer: Executive V.P. CFO 590 E. MIDDLEFEILD ROAD, MOUNTAIN VIEW CA 94043
Mary Garrett director ETHAN ALLEN DRIVE, DANBURY CT 06811
Manley Corey J officer: SR. VP & CHIEF LEGAL OFFICER 590 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Dan S Johnston officer: V.P., Legal & General Counsel
Joseph Brian Spears officer: Chief Accounting Officer & VP 590 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
James T Judson officer: VP Finance & Acting CFO C/O OMNICELL, INC., 1201 CHARLESTON ROAD, MOUNTAIN VIEW CA 94043
Robin Gene Seim officer: V.P., Finance & CFO 1201 CHARLESTON ROAD, MOUNTAIN VIEW CA 94043
Edward Peter Bousa director 280 CONGRESS STREET, BOSTON MA 02210